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Abstract
Purpose To assess the impacts of erythromycin on the
pharmacokinetics of voriconazole and its association with
CYP2C19 genotypes in healthy Chinese male subjects.
Methods A single-center, open, crossover clinical study
with two treatment phases was carried out. Eighteen healthy
male volunteers, including 6 CYP2C19 homozygous exten-
sive metabolizers (EMs, *1/*1), 6 heterozygous EMs
(HEMs, *1/*2 or *1/*3), and 6 CYP2C19 poor metabo-
lizers (PMs, *2/*2 or *2/*3), were enrolled in this study. A
single oral dose of 200 mg voriconazole was administrated
to all subjects after 3-day pretreatment with either 500 mg
erythromycin or placebo three times daily. Periods were
separated by a washout period of 14 days. Serial venous
blood samples were collected, and plasma concentrations of
voriconazole were determined by HPLC.
Results Cmax, AUC0–24, and AUC0 1 of voriconazole were
increased significantly, while oral clearance of voriconazole
was decreased significantly by erythromycin administration
(p<0.001, respectively). Compared with individuals with
CYP2C19 PM genotypes, individuals with CYP2C19 EM
and HEM genotypes showed significantly decreased T½,
AUC0–24, AUC0 1, and increased oral clearance of
voriconazole (p<0.05, respectively). In addition, significant
increases in AUC0–24 and AUC0 1 and decreases in oral
clearance of voriconazole after erythromycin treatment
were observed in CYP2C19 HEMs and PMs (p<0.05,
respectively), but not in CYP2C19 EMs.
Conclusion Both CYP2C19 genotypes and CYP3A4 inhib-
itor erythromycin can influence the plasma concentration of
voriconazole, and erythromycin increases plasma concen-
tration of voriconazole in a CYP2C19 genotype-dependent
manner.
Keywords Voriconazole.Erythromycin.CYP2C19.
Genetic polymorphism.Chinese
Introduction
Voriconazole is a second-generation triazole antifungal
agent that is structurally related to fluconazole. The
mechanism of action of voriconazole is similar to that of
other azoles, i.e., it inhibits the cytochrome P450-dependent
14-α-lanosterol demethylase and disrupts fungal ergosterol
synthesis [1–4]. Voriconazole is used for the treatment of
invasive aspergillosis and other serious infections [5–8].
Voriconazole undergoes extensive oxidative metabolism
mediatedbycytochromeP450(CYP)isoformsCYP2C19and
CYP3A4, and to a lesser extent, by CYP2C9 [9, 10].
Mutations in the CYP2C19 gene that result in the CYP2C19
poor metabolism (PM) phenotype are common in Asians.
About 13–23% of Asians inherit CYP2C19 PM genotypes,
which is a much higher prevalence than 3–5% observed in
Caucasians [11–14]. Evidence has shown that 49% of the
variance in apparent oral clearance of voriconazole can be
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suggested that the initiation dose of voriconazole dosage
should be adjusted according to CYP2C19 genotypes to
avoid hepatotoxicity [16]. Preliminary observations also
suggest that CYP2C19 genotypes should be evaluated as a
factor that may affect the pharmacokinetics of voriconazole
and perhaps drug interactions or adverse events related to
voriconazole [17–19].
CYP3A4 is a major drug metabolic enzyme in adult
humans, and contributes to the metabolism of about 70%
clinically important medications [20]. Induction or inhibi-
tion of CYP3A4 as a result of drug interactions is common
in clinical practice. During the treatment of systemic
fungal infection, antifungal agents such as voriconazole
are often prescribed concomitantly with other medicines,
and some of these latter medicines are CYP3A4 inhibitors
[21]. Erythromycin has proven to be a potent CYP3A4
inhibitor that can result in mechanism-based inactivation of
CYP3A4 [22–24]. Results from in vitro study indicate that
erythromycin affects voriconazole metabolism [10], although
the clinic relevance of this drug interaction remains to be
explored.
This study was designed to assess the impacts of
erythromycin on pharmacokinetics of voriconazole, and to
identify the potential role of CYP2C19 variants in the
magnitude of this drug–drug interaction in healthy Chinese
male subjects. We expect that the results of this study
would be helpful in the optimization of voriconazole
therapy in the clinic.
Materials and methods
Subjects
Two hundred and ninety-seven unrelated Chinese male
healthy volunteers were genotyped for CYP2C19*2 and
CYP2C19*3 variations. Six individuals homozygous for the
wild-type allele (CYP2C19*1/*1, denoted EM), 6 individuals
heterozygous for the CYP2C9*2 or CYP2C9*3 variants (n=
4f o rt h eCYP2C9*1/*2 genotype and n=2 for the
CYP2C9*1/*3 genotype, denoted HEM) , and 6 individuals
carrying two variant alleles simultaneously (n=5 for the
CYP2C19*2/*2 genotype and n=1 for the CYP2C19*2/*3
genotype, denoted PM) were then selected randomly from
these subjects. The mean age of the volunteers ranged from
19 to 23 years and the range of body mass index was
approximately 18–25 kg/m
2. No significant difference in
either mean age or body mass index was observed among the
three genotyped groups.
All subjects were ascertained to be in good health as
identified from medical history, routine physical examina-
tion, and clinical laboratory tests. None of the volunteers
was a smoker or had received any medication of botanical
dietary supplements at least 2 weeks before entry into and
during the study. All subjects ate a normal diet during the
study. The study protocol was approved by the Ethics
committee of Xiangya School of Medicine, Central South
University. Written informed consent was obtained from all
volunteers.
Study design
The study was carried out as a single-center, randomized,
open, crossover design with two treatment phases, separated
by a 2-week washout period. The subjects were hospitalized
during the investigational treatments (from day 1 to the
morning in day 5) in each phase. In each phase, the 18
volunteers received oral administration of either placebo or
erythromycin (4 tablets erythromycin enteric-coated
125 mg; Baiyunshan, Guangzhou, China; batch
No.1060001) three times daily for 4 days (day 1 to
day 4) for 12 doses (the tenth dose being administered
30 min ahead of the voriconazole dose on the morning of
day 4). On day 4, each subject was given a single oral
dose of 200 mg voriconazole (four tablets of voricona-
zole 50 mg; GeneTech Pharm, Beijing, China; batch
No. 20051001, this dose level is recommended in
clinical use) along with 200 mL plain water after
overnight fasting and rest. The subjects were asked to
b er e c u m b e n tf r o m3 0m i nb e f o r et o4ha f t e rt h e
administration of drugs. Standardized meals were
served at 2 h, 4 h, and 10 h respectively, after morning
drug dosing. All subjects were under close surveillance
by appropriately qualified staff within 24 h after
voriconazole administration.
Venous blood samples for the determination of plasma
concentrations of voriconazole were collected immediately
before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after
the administration of voriconazole. Blood was collected into
4-mL EDTA-containing vacuum blood-collecting tubes.
Immediately after blood collection, the samples were
centrifuged at 3,000 rpm for 10 min. The plasma was
transferred into polypropylene tubes and stored at −40°C
until analysis.
CYP2C19 genotyping
Genomic deoxyribonucleic acid (DNA) samples were
extracted from venous blood samples by standard phenol/
chloroform extraction. Detection of CYP2C19*2 and
CYP2C19*3 mutant alleles was performed by PCR/RFLP,
as described elsewhere [25–27]. PCR products were
digested with the restriction endonucleases Sma I and
BamH It od e t e c tt h eCYP2C19*2 allele and the
CYP2C19*3 allele respectively. DNA fragments generated
1132 Eur J Clin Pharmacol (2010) 66:1131–1136after restriction enzyme digestion were separated on a 2%
agarose gel. Restriction fragments were visualized by use of
a UV detector.
High performance liquid chromatography determination
of the plasma concentration of voriconazole
Plasma concentrations of voriconazole were determined
by high performance liquid chromatography (HPLC) as
described with optimization [28]. Plasma samples were
extracted with chloroform. Chromatographic column was
Diamonsil C18 (250 mm×4.6 mm, 5 μm); the mobile
phase was composed of acetonitrile: 10 mM ammonium
acetate (pH set at 5.4 with acetic acid) with a v:v of 50:50;
the flow rate was 1.0 mL/min; the column temperature was
40°C and the detector wavelength was set at 255 nm. The
standard curves of voriconazole were constructed with
eight non-zero standards ranging from 0.02 μg/mL to
8.86 μg/mL. The lower limit of quantification was
0.02 μg/mL and the concentrations of QC samples were
0.07, 1.10 and 8.80 μg/mL respectively.
Safety analysis
All adverse events reported spontaneously by the subjects
or observed during the subjects’ surveillance were docu-
mented, including times of onset and resolution, intensity,
and causal relationship to the study drug. Vital signs
including blood pressure and pulse rate were surveyed
regularly during the hospitalization period.
Pharmacokinetic analysis
The peak concentration (Cmax) and concentration peak time
(tmax) were obtained directly from the observed data. The
elimination half-life (t½), the area under the plasma
concentration–time curve (AUC0–24), AUC from zero to
infinity (0-∞) and the apparent oral clearance (CLoral/F)
were calculated by DAS 2.0 (Gaosi Data Analysis, Wuhu,
China).
Statistical analysis
Statistical analyses were carried out with SPSS software
version 11.0 for Windows (SPSS, Chicago, IL, USA). Data
were expressed as mean±SD. Differences in pharmacoki-
netic parameters and ratios in different treated phases
within the same genotype and pharmacokinetic parameters
among different genotypes were compared using t test or
ANOVA respectively. Wilcoxon’s signed-rank test was
used to compare difference in tmax between or among
different groups. A p value <0.05 was considered to be
statistically significant.
Results
Safety of voriconazole after oral administration
Voriconazole was generally well tolerated by all participants,
without serious adverse events. One participant with the
CYP2C19*2/*2 genotype discontinued the study after the
first phase because of a heavy cold.
Erythromycin increased the plasma concentration
of voriconazole
Figure 1 showed the plasma concentration–time curves of
voriconazole with a 4-day treatment with erythromycin and
placebo. Compared with the placebo-treated phase, the
Cmax (2.36±0.78 μg/mL vs 3.16±0.76 μg/mL, p<0.001),
AUC0–24 (12.65±10.15 μg·h/mL vs 18.97±13.86 μg·h/mL,
p<0.001), AUC0 1 (15.62±15.11 μg·h/mL vs 23.63±
20.45 μg·h/mL, p<0.001) of voriconazole was increased
significantly in the erythromycin treated phase, while the
CLoral/F of voriconazole was decreased significantly by 4-
day erythromycin treatment (381±244 mL/min vs 245±
171 mL/min, p<0.001, Table 1). No significant difference
in T½ and Tmax was observed between the placebo- and
erythromycin-treated phases (Table 1).
CYP2C19 PM genotype increased the plasma concentration
of voriconazole in the placebo-treated phase
Plasma concentration–time curves of voriconazole according to
CYP2C19 genotypes in the placebo-treated phase are shown
in Fig. 2. Significant differences in T½, AUC0–24,A U C 0 1,
and oral clearance of voriconazole were observed among
CYP2C19 genotypes (p<0.05, Table 1). Compared with
individuals with CYP2C19 PM genotypes, individuals with
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Fig. 1 Mean (± SD) voriconazole plasma concentration–time profile
after single oral administration of 200 mg voriconazole in all 18
subjects with a 4-day treatment with placebo (squares) or erythromy-
cin (black circles)
Eur J Clin Pharmacol (2010) 66:1131–1136 1133EM and HEM genotypes showed significantly decreased T½,
AUC0–24,A U C 0 1, and increased oral clearance of vorico-
nazole (p<0.05 respectively, Table 1). No significant differ-
ence in any of the pharmacokinetics parameters of
voriconazole between EM and HEM genotypes was observed
in the placebo-treated phase (Table 1).
Effect of erythromycin on voriconazole pharmacokinetics
is associated with CYP2C19 genotypes
We then analyzed the effect of erythromycin on the
pharmacokinetics of voriconazole according to CYP2C19
genotypes. The pharmacokinetics profile and detailed
pharmacokinetic parameters are shown in Fig. 3 and Table 1
respectively. Both AUC0–24 (p<0.05 for PM, and p<0.01
for HEM) and AUC0 1 (p<0.01 for both PM and HEM)
was increased significantly after erythromycin treatment in
CYP2C19 HEM and PM individuals, but not in CYP2C19
EM individuals. CLoral/F of voriconazole was decreased
obviously after erythromycin treatment in the CYP2C19
HEM and PM individuals (p<0.05 for PM, and p<0.01 for
HEM), but not in the CYP2C19 EM individuals. However,
the Cmax of voriconazole was increased significantly in
individuals with the CYP2C19 EM (p<0.01) and HEM (p<
0.05) individuals, but not PM individuals after erythromy-
cin treatment. No significant difference in T½ and Tmax of
voriconazole was observed between placebo- and
erythromycin-treated phases for any of the CYP2C19
genotypes.
Discussion
In the consideration that the antifungal agent voriconazole
might be used concomitantly with the erythromycin, a potent
CYP3A4 inhibitor, we observed the effect of 4-day erythro-
mycin administration on the pharmacokinetics of voriconazole,
and assessed the association of CYP2C19 variants
(CYP2C19*2 and CYP2C19*3)w i t ht h i sd r u g –drug interac-
tion in healthy Chinese male subjects. We observed that both
4-day treatment with erythromycin and CYP2C19 PM
genotypes increased the plasma concentration of voriconazole
and decreased its oral clearance. We also observed a
significant erythromycin–CYP2C19 genotype interaction in-
fluencing plasma concentration of voriconazole in these
individuals, and erythromycin treatment increased the AUC
and decreased oral clearance of voriconazole limited to
CYP2C19 HEM and PM, but not CYP2C19 EM individuals.
Our observation that T½,C max, AUC0–24, AUC0 1 was
increased and CLoral/F was decreased in CYP2C19 PMs
compared with CYP2C19 EMs in the placebo-treated phase
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Fig. 2 Mean (± SD) voriconazole plasma concentration–time profile
after single oral administration of 200 mg of voriconazole according to
CYP2C19 genotypes in the placebo treatment phase. EMextensive
metabolizers, HEM heterozygous extensive metabolizers, PM poor
metabolizers
Table 1 Pharmacokinetic parameters of voriconazole in healthy Chinese volunteers with different CYP2C19 genotypes with a 4-day treatment
with placebo or erythromycin
All volunteers (n=18) CYP2C19 EM (n=6) CYP2C19 HEM (n=6) CYP2C19 PM (n=6)
Placebo Erythromycin Placebo Erythromycin Placebo Erythromycin Placebo Erythromycin
AUC0–24 (h·μg/mL) 12.65±10.15 18.97±13.86## 7.05±2.99** 8.54±2.59 8.60±5.62** 15.65±7.36## 24.23±11.05 35.47±13.13#
AUC0 1 h   mg=mL ðÞ 15.62±15.11 23.63±20.45## 7.70±2.99** 10.75±5.32 10.75±9.42** 16.95±8.10## 30.95±19.20 47.09±23.50##
Cmax (μg/mL) 2.36±0.78 3.16±0.76## 2.22±0.77 3.04±0.63## 2.29±0.47 2.80±0.68# 3.03±0.75 3.75±0.76
CLoral/F (mL/min) 381±244 245±171## 499±228* 375±176 452±233* 240±125# 153±110 93±64##
T½ (h) 5.31±3.96 6.57±4.44 3.72±2.12* 3.76±2.51 4.09±2.84
* 5.80±3.14 8.69±5.17 10.87±4.79
Tmax (h) 1.41±0.64 1.12±0.60 1.25±0.69 0.67±0.26 1.50±0.63 1.00±0.45 1.50±0.71 1.80±0.45
EM, extensive metabolizers; HEM, heterozygous extensive metabolizers; PM, poor metabolizers, AUC0–24, mean total area under the plasma
concentration–time curve from time 0 to 24 h; AUC0 1, mean total area under the plasma concentration–time curve from time 0 to ∞;C max, peak
plasma concentration; CL/F, oral clearance; T½, terminal elimination half-life; tmax, time to peak plasma concentration
Values are mean±SD
#p<0.05, ##p<0.01 compared with placebo in corresponding CYP2C19 genotype
*p<0.05, **p<0.01 compared with CYP2C19 PM genotype after placebo treatment.
1134 Eur J Clin Pharmacol (2010) 66:1131–1136is in agreement with several previous studies [18, 19, 29,
30], which indicates that CYP2C19 genotypes are a key
factor in the determination of voriconazole metabolism.
In vitro study indicates that the Michaelis–Menten constant
(Km) of voriconazole oxidase activity by CYP2C19 was
obviously lower than that by CYP3A4. Therefore, CYP3A4-
mediated metabolism may not be the main pathway of
voriconazole elimination [9, 10]. Previous in vivo and in
vitro studies have also investigated the effect of CYP3A4
inhibitors on metabolism of voriconazole [10, 29]. However,
controversial observations are reported [10, 29]. A study by
Purkins et al. suggests that erythromycin does not affect the
steady-state pharmacokinetics of voriconazole [29]. However,
the study design of ours is very different from that of Purkins
et al. In their study, voriconazole was given 200 mg twice
daily for 14 days, while erythromycin was given twice daily
during day 8 to day 14 after initiation of voriconazole
administration, and pharmacokinetics of voriconazole was
analyzed on days 7 and 14 [29]. However, it is reported that
voriconazole can also inhibit CYP3A4 [9, 10] and thus may
inhibit its own metabolism after long-term use, while in our
study, erythromycin was administered for 3 days before a
single oral dose of voriconazole. Our results suggest that
erythromycin can obviously affect the pharmacokinetics of
voriconazole. As both erythromycin and voriconazole can
inhibit CYP3A4, the interactions between erythromycin and
voriconazole are more complicated in vivo, if voriconazole
has reached its steady-state after repeated doses, the effects of
CYP3A4 inhibitors may not change voriconazole metabo-
lism. However, if CYP3A4 inhibitors are given before
voriconazole, voriconazole metabolism will be affected.
Further research is needed to study the effects of CYP3A4
inhibitors on the pharmacokinetics of voriconazole.
Because CYP2C19 is a major enzyme involved in
voriconazole metabolism [9, 10], and CYP2C19 genetic
polymorphism can also affect the pharmacokinetics of
voriconazole, we hypothesize in our study that the CYP2C19
genetic polymorphism might interact with erythromycin in
affecting voriconazole metabolism. We observed that the
increases in AUC0 1 and decreases in CLoral/F of voricona-
zole by erythromycin pretreatment were significantly different
among CYP2C19 genotypes. In both the CYP2C19 HEM and
PM individuals, AUC of voriconazole increased significantly
while oral clearance of voriconazole decreased significantly
after erythromycin treatment. However, in individuals with
the CYP2C19 EM genotypes, the changes in AUC and oral
clearance of voriconazole were not obvious after erythromy-
cin treatment. These findings indicate a drug–gene interaction
in the inhibition of voriconazole metabolism by erythromy-
cin, and CYP3A4 might be important for voriconazole
metabolism in CYP2C19 HEM and PM individuals.
Because CYP2C19 genetic analysis for this study
included only alleles *2 and *3, the two major mutant
alleles of CYP2C19, comprising almost 100% of the PMs
in oriental populations [12, 26], the occurrence of other
defective alleles in the study population and thus misclas-
sification of individuals cannot be ruled out.
In conclusion, this study provides further evidence for
the determination of CYP2C19 genotypes in voriconazole
metabolism, and find that pretreatment with the CYP3A4
inhibitor erythromycin can increase the plasma concentra-
tion of voriconazole in a CYP2C19 genotype-dependent
manner. Therefore, combination therapy with erythromycin or
other CYP3A4 inhibitors and voriconazole may result in higher
antifungal exposure, especially in CYP2C19 PM and HEM
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Fig. 3 Mean (± SD)plasma concentration–time profile of voricona-
zole after a single oral administration of 200 mg of voriconazole
pretreated with placebo or erythromycin and association with
CYP2C19 genotypes
Eur J Clin Pharmacol (2010) 66:1131–1136 1135individuals. At the same time, attention should be paid to
dose-limiting adverse events of voriconazole, such as
hepatotoxicity, when CYP2C19 PM and HEM patients
undergo concomitant voriconazole and erythromycin therapy.
Considering the results of our study and previous findings,
we would suggest that the voriconazole dosage might
be reduced for CYP2C19 PM and HEM individuals, as
lower doses in PM and HEM can meet the required
effective therapeutic level and decrease the adverse events
of voriconazole.
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